Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults

The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSV∆G-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak

(2018) Mohamed Samai et al.   JOURNAL OF INFECTIOUS DISEASES

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study

(2018) Angela Huttner et al.   LANCET INFECTIOUS DISEASES

A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus

(2018) Bronwyn M. Gunn et al.   Cell Host & Microbe

Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea

(2018) Aitana Juan-Giner et al.   VACCINE

Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults

(2017) Scott A. Halperin et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)

(2017) Ana Maria Henao-Restrepo et al.   LANCET

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study

(2017) D Gray Heppner et al.   LANCET INFECTIOUS DISEASES

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine

(2017) Jason A. Regules et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia

(2017) Stephen B. Kennedy et al.   NEW ENGLAND JOURNAL OF MEDICINE

After Ebola in West Africa — Unpredictable Risks, Preventable Epidemics

(2016)   NEW ENGLAND JOURNAL OF MEDICINE

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

(2016) Selidji T. Agnandji et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial

(2015) Ana Maria Henao-Restrepo et al.   LANCET

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

(2015) Angela Huttner et al.   LANCET INFECTIOUS DISEASES

VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain

(2015) A. Marzi et al.   SCIENCE

Ebola virus vaccines: an overview of current approaches

(2014) Andrea Marzi et al.   Expert Review of Vaccines

Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates

(2013) A. Marzi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates

(2012) Chad E. Mire et al.   PLoS Neglected Tropical Diseases

Vesicular Stomatitis Virus–Based Ebola Vaccines With Improved Cross-Protective Efficacy

(2011) Andrea Marzi et al.   JOURNAL OF INFECTIOUS DISEASES

Ebola haemorrhagic fever

(2010) Heinz Feldmann et al.   LANCET

Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses

(2009) Xiangguo Qiu et al.   PLoS One

Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates

(2008) Thomas W. Geisbert et al.   PLoS Pathogens